What sets TARA-002 apart is its novel approach. This cell therapy is derived from a cell bank of genetically distinct Streptococcus pyogenes, already approved in Japan as the broad immunopotentiator OK-432. The therapy works through a dual mechanism – directly killing tumor cells while also stimulating an immune response known as immunogenic cell death, thereby amplifying antitumor activity.The first penny stock we’ll look at is Protara Therapeutics, a clinical-stage biotech company focused on developing tr ...